Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TP53 mutation in colorectal cancer.

Barry Iacopetta1

  • 1Department of Surgery, University of Western Australia, Nedlands, Australia. bjiac@cyllene.uwa.edu.au

Human Mutation
|March 6, 2003
PubMed
Summary

TP53 gene mutations are common in colorectal cancer but lack prognostic value. However, normal p53 is crucial for chemotherapy response, suggesting p53 status could guide treatment decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.

Oncology letters·2018
Same author

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.

Oncotarget·2018
Same author

Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.

Pathology·2018
Same author

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

Oncotarget·2018
Same author

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018
Same author

Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis.

Oncotarget·2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • TP53 gene mutations occur in about half of colorectal cancers (CRCs).
  • Mutation frequencies vary by tumor location and molecular subtype (microsatellite instability/methylator phenotypes).
  • TP53 alterations have limited prognostic value in surgically treated patients but correlate with poorer survival in those receiving chemotherapy.

Purpose of the Study:

  • To investigate the role of TP53 gene status in colorectal cancer prognosis and response to chemotherapy.
  • To evaluate the potential of p53 overexpression as a predictive marker for 5-fluorouracil-based chemotherapy.

Main Methods:

  • Review of existing in vitro, animal, and clinical studies.
  • Analysis of TP53 mutation frequencies in different CRC subtypes.
  • Evaluation of p53 overexpression via immunohistochemistry (IHC).

Main Results:

  • TP53 mutations are frequent in distal colon and rectal tumors, less so in proximal tumors and MSI/methylator phenotypes.
  • TP53 status shows little prognostic value for surgery alone but is linked to worse survival with chemotherapy.
  • Normal p53 function appears necessary for response to 5-fluorouracil-based chemotherapy.

Conclusions:

  • TP53 gene status has minimal prognostic impact in colorectal cancer patients treated with surgery alone.
  • Normal p53 is essential for effective 5-fluorouracil chemotherapy response in colorectal cancer.
  • Standardized IHC evaluation of p53 overexpression may identify patients who will benefit from current chemotherapy regimens.

Related Experiment Videos